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An Investigation into the Antifungal Activities of N-Thiolated 
β−Lactams Against Selected Candida Species 
Marci Culbreath 
ABSTRACT 
β-lactam antibiotics have long been a reliable course of treatment for bacterial 
infections.  However, with recent increases in resistance and rising populations of 
immunocompromised patients new β-lactams have been synthesized and tested.  The 
Turos laboratory has recently discovered novel β-lactams that have a mode of action 
distinct from penicillin and other β-lactam antibiotics as cell lysis is not observed.  In the 
current investigations, these compounds are shown to also have antifungal properties.  
The rising incidence and prevalence of invasive fungal infections has become an 
increasing concern.  The most common fungal pathogens involved in these infections are 
species in the genus Candida.  In this study antifungal activity is observed for a wide 
range of N-methylthio β-lactams against C. albicans, C. tropicalis, C. keyfr, C. glabrata, 
C. lusitinae, C. utilis, and C. parapsilosis.  The structure-activity relationship based on 
studies of β−lactam derivatives leaving different substituents at various positions on the 
lactam ring are investigated, and the minimum inhibitory concentration values 
determined using standard methods.  In studies towards understanding the mode of 
action, the products of the interaction between the drug and fungal cells in a suspension 
were investigated using nuclear magnetic resonance spectroscopy and transmission 
 vii
electron microscopy.  The mode of action of these new lactams seems to be similar to 
that observed in bacteria, involving transfer of the methylthio group to a cellular thiol. 
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Chapter One 
Introduction 
Rising Incidence and Prevalence of Candida Infections 
 The rising incidence and prevalence of invasive fungal infections 
has become an increasing concern.  Candida species are the most 
frequently isolated human fungal pathogens.1  Usually harmless 
commensal organisms, they are part of the normal human 
microflora of the mouth and gastrointestinal tract.2  However, in a 
state of altered homeostasis such as occurs during treatment with 
broad-spectrum antibiotics or in immunocompromized patients, 
Candida species are potent opportunistic pathogens.3  They are 
capable of producing infections at almost any site, varying in 
intensity from acute localized infections to serious invasive 
infections (candidiasis, candidemia).4 
 The incidence of invasive candidiasis and candidemia has risen 
rapidly over the past 20 years and has become a significant 
problem.5  Candida is now the fourth most common cause of 
nosocomial bloodstream infections in the US, surpassing gram 
negative bacilli in frequency.6  Candida infections account for 8 % of 
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all septicemias.7  The patient population at risk for infection by 
Candida has also grown to include thse undergoing solid organ and 
stem cell transplants, those being treated for cancer, 
immunosuppressive therapy, AIDS, and those from premature 
birth, with advanced age and recovering from major surgery.8 The 
tremendous impact of these infections are apparent in terms of 
cost, morbidity and mortality.  Most strikingly the attributable 
mortality to disseminated Candida infection is almost 50%.9 
 
Etiology of Invasive Fungal Infections 
 The etiology of Candida infections has also changed over the 
past twenty years.  Candida albicans has long been and continues 
to be the leading etiologic agent of Candida infections.  However, 
more recently there has been a growth in the number of cases of 
non-albicans Candida infections.10  Non-albicans species now 
account for greater then fifty percent of infections.11  The increased 
use of azoles such as fluconazole have positively selected for such 
less sensitive or resistant species as Candida krusei, Candida 
lusitaniae, and Candida glabrata.12 Candida glabrata is now the 
second most frequent causative agent of candidemia in the US.13  
Candida glabrata has been associated with a digestive or urinary 
point of entry, especially with catheters.14   Candida krusei has 
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been found in patients with solid tumors or leukemia.14   Candida 
lusitaniae is associated with urinary and respiratory infections as 
well as those arising from intravenous catheters and use of broad-
spectrum antibiotics.14    Both C. parapsilosis and C. tropicalis have 
been associated with use of intravenous catheters, contamination 
of the infusate, and colonization of health care workers.14  C. 
tropicalis most frequently appears in patients with cancer or 
leukemia, and C. parapsilosis often occurs with long term 
parenteral alimentation.14  Interestingly, in other parts of the 
world, specifically in Latin American countries, C. tropicalis and C. 
parapsilosis usurp C. glabrata as the second most common agent 
of candidemia.15  The reasons for this are not well known.   
 Apparently, the genus Candida and the infections that result 
include a rather disparate group of organisms that can grow as 
yeasts, but are not as closely related as one might expect of 
species in a single genus,16 evidenced by the variation of risk 
factors and even geographical differences in etiology.  This 
presents a challenge in treatment as even the best currently 
available drugs are plagued by intrinsic and acquired resistance. 
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Overview of Current Therapies 
 Most antifungals target ergosterol biosynthesis.  This pathway 
converts acetic acid to the membrane sterol, ergosterol, using 
many of the same enzymes that mammalian cells use to produce 
cholesterol.17  There are however several enzymatic steps that are 
unique to the ergosterol pathway which are the targets for 
antifungals.  The agents currently in use can be grouped into 
several classes by their mode of action. 
Polyenes 
 The polyenes, including amphotericin B (Figure 1)  and nystatin, 
are the broadest spectrum antifungals available.  They are 
fungicidal, causing cell death by intercalating with the ergosterol in 
the membrane bilayer to produce small pores.18 These pores 
destroy the proton gradient by leaking cations, depolarizing the cell 
and eventually causing cell death.19   
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Figure 1: Structure of Amphotericin B 
 
 Amphotericin B delivered intravenously has been the drug of 
choice for disseminated candidiasis.20  Despite its potent antifungal 
properties, amphotericin B has well documented toxicity as it also 
binds to cholesterol.21,22  The most serious side effect is 
nephrotoxicity. There have also been reports of both intrinsic 
resistance and acquired resistance in C. lusitaniae attributable to 
changes in membrane sterols.23 
Antimetabolites 
 Antimetabolites such as 5-flucytosine (Figure 2) disrupt DNA and 
protein synthesis.  5-Flucytosine is a nucleoside analogue that 
causes DNA miscoding.24 Since resistance to this drug develops  
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rapidly,25 it is used in combination with amphotericin B in treatment 
of Candida endophtalmitis.20 
 
Figure 2: Structure of 5-flucytosine 
 
Azoles 
 Azoles include imidizoles (clotrimazole, miconizole, and 
ketoconazole (Figure 3)) and triazoles (fluconazole (Figure 4)and 
itraconazole).  Azoles inhibit cytochrome P450 dependent enzymes, 
more specifically, lanosterol demethylase, which is responsible for 
the conversion of lanosterol into ergosterol.26  This inhibition does 
not completely block the pathway at this point, but rather the 
methylated lanosterol is acted upon by enzymes downstream in the 
pathway to produce a toxic intermediate which is responsible for 
growth inhibition.27 
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Figure 3: Structure of Ketoconazole 
 
 
Figure 4: Structure of Fluconazole 
 
 These drugs have substantially fewer side effects than 
amphotericin B and are effective against oropharangeal and vaginal 
candidiasis.  They are also used as prophylaxis for fungal infection 
in preparation for bone marrow transplantation and to prevent oral 
candidiasis in HIV patients.20  However, many non-albicans species 
such as C. krusei and C. glabrata have innate resistance, and 
acquired resistance has been observed through several 
mechanisms.1  As stated earlier it is thought that the use of azoles 
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has contributed to the rise in incidence of these resistant species. 
Echinocandins 
 The newest classes of antifungal agents include the 
echinocandins and their analogues, the pneumocandins.  The first of 
which to be commercially available is caspofungin (Figure 5) They 
inhibit 1,3-β-D-glucan synthase which is responsible for forming 
polymers of 1,3-β-D-glucan, a component of the fungal cell wall.28  
These drugs are very promising because little resistance has been 
reported even in fluconazole-resistant strains.29  Also, since 
mammalian cells do not contain 1,3-β-D-glucan, there is little 
toxicity.30 
 9
 
Figure 5: Structure of Caspofungin 
 
 As discussed antifungals currently in use can be grouped by their 
function, figure 6 depicts a generalized fungal cell and the sites of 
antifungal drug action. 
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Figure 6: Generalized Fungal Cell Showing Sites of Antifungal Drug 
Activity 
 
 
Emerging Resistance 
 As discussed in the previous section resistance is a growing 
problem for even the newest of antifungal drugs.  Both primary (or 
intrinsic) resistance and secondary (or acquired) resistance have 
been observed in Candida species. Mechanisms of resistance have 
been studied in great detail in many isolates of C. albicans and to a 
lesser extent in C. glabrata, C. tropicalis, and C. krusei.25  Acquired 
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antifungal resistance mechanisms tend to follow three distinct 
strategies: increased efflux, alteration of the targeted enzyme, and 
alteration of metabolism.  
  Increased efflux is the main mechanism of azole resistance and 
results from an overexpression of ATP-binding cassette (ABC) 
transporter genes CDR1 and CDR2 from C. albicans,31 CgCDR1 and 
PDH1 from C. glabrata,32 and the major facilitator (MF) gene 
MDR1.33  The major difference between these two types of 
transporters is that ABC transporters will pump out almost all azoles 
whereas MF transporters only accept fluconazole.25 
  Alteration in the target enzyme either prevents the enzyme 
from binding the drug or prevents allosteric inactivation of the 
enzyme after binding of the drug.  Target enzymes can also be 
overexpressed, resulting in activity despite the presence of the 
drug.  Resistance to capsofungin is thought to be an example of 
this, a result of a mutation in glucan synthase.17 
  Alteration of metabolism refers to a mutation that prevents the 
buildup of a toxic metabolite resulting from the presence of the 
drug. This can also refer to tolerance pathways.17 
  The fourth and much less documented mechanism is the 
alteration in sterol concentration, in which ergosterol is replaced by 
7, 22-dieneol- 3-β-ol. This results in both azole and amphotericin B 
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resistance.17 
 Since even the newest drugs have documented resistance, the 
continued study of antifungal resistance, the search for new cellular 
targets and the development of novel antifungal drugs are of the 
upmost importance. 
 
N-Thiolated β-Lactams 
Our laboratory has been investigating a new series of monocyclic 
N-thiolated β-lactams that act selectively on drug-resistant strains 
of Staphylococcus bacteria.34  β-Lactam antibiotics have long been a 
reliable course of treatment for bacterial infections.  Older β-
lactams such as penicillin act by inhibiting peptidoglycan 
transpeptidation which is essential for bacterial cell wall synthesis.  
This eventually leads to cell death.35   
 
N
S
O
CH3
CH3
H
N
COOH
O
R
                     
N
SRO
R3 R4  
Figure 7: Structure of penicillin versus N-thiolated β-lactam 
 13
However, no cell wall deformation or cytoplasmic leakage is 
observed with N-thiolated β-lactams in S. aureus bacteria.34 
Additionally, these compounds differ structurally from older β-
lactams in that they lack the acidic ring functionality required for 
recognition by penicillin binding proteins as shown in Figure 7, and 
an N-organothio substituent is strictly required for biological 
activity. This indicated that these compounds display a mode of 
action distinct from that of older β-lactams.34  
Fungal cell walls do not contain peptidoglycan therefore older 
β-lactam antibiotics are ineffective against fungal infections. Modest 
antifungal activity has in the past been observed in some 
semisynthetic β-lactam containing compounds, such as those shown 
in Figure 8.36  Clavams have also been found to be both 
bacteriostatic and fungistatic by distinct modes of action.37 
N
S
C6H5CH2NHCSCH2CONH
O
CO2Na
CH2OCOCH3
N
S
R"
O
R'NH
 
R’=C6H5OCH2CO; R”=CHO 
R’=C6H5OCH(CH3)CO; R”=COSK 
Figure 8: Structures of Previously Reported Antifungal β-lactam 
Containing Compounds   
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Thus, testing was performed to ascertain the activity of N-
thiolated β−lactams against 8 Candida species, and after finding 
bioactivity, preliminary studies were conducted towards 
determining the mode of action. 
 
Synthesis 
  Monocyclic N-thiolated β−lactams can be readily synthesized 
from commercially available precursors as previously reported by 
our laboratory.38  The synthesis begins with a condensation of an 
aldehyde with p-anisidine to form an imine.  A Staudinger reaction 
or an acid chloride and the imine produces the N-protected 
β−lactam.  Cerium ammonium nitrate is then used to remove the 
aryl protecting group.  Finally, the deprotected lactam is N-
alkylthiolated with an N-alkylthio phthalimide.  This is depicted in 
Figure 9. All compounds in this study were obtained in racemic form 
as solely the cis-diastereomers. 
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Figure 9: Synthesis of N-thiolated β−lactams 
 
  Syntheses of three monocyclic N-thiolated  β−lactams were 
completed in this study.  Their structures are depicted in Figure 10. 
Lactams A and B were novel analogues.  The proton NMR spectra  
can be found in Appendix A. 
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N
O SMe
MeO
Cl
N
O S
MeO
N
O SMe
MeO
  
       Lactam 4   Lactam A   Lactam B 
Figure 10: Structures of Lactams Synthesized 
 
 Hundreds of analogues of monocyclic N-thiolated  β−lactams 
have been prepared by members of our laboratory. Twenty five 
previously synthesized lactams numbered 1-25 were also used in 
this study. 
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Chapter Two 
 
Studies on Antifungal Activity 
 
Species of Candida were chosen based on their potential for 
pathogenicity.  The following fungi were used for the antifungal 
evaluation of these N-thiolated β-lactams : Candida albicans (ATCC 
1111), Candida glabrata (ATCC 15126), Candida tropicalis (ATCC 
1111), Candida parapsilosis (ATCC 1111), Candida krusei (ATCC 
14243), Candida lusitaniae (ATCC 34449), Candida kefyr (ATCC 
20409), and Candida utilis (ATCC 29950).  Fungi were obtained 
commercially.  Two additional Candida isolates, C. albicans and C. 
tropicalis, were donated by Dr. Ray Widen from the University of 
South Florida School of Medicine.   
Spectrum of activity against Candida species 
Previously synthesized lactams were screened against 8 different 
Candida species.  The method of testing used to screen for activity 
was disk diffusion susceptibility testing.39  Although MIC (minimum 
inhibitory concentration) values are often used as the ideal 
susceptibility measure, the insolubility of these compounds in 
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aqueous media made MIC determinations impractical for the 
preliminary study. 
 
Method 
 Culture preparation: A culture of each organism was grown on 
Yeast Nutrient Agar (Difco, MI) from a freezer stock in Yeast 
Nutrient Broth (Difco Laboratories, MI) and glycerol.  Plates were 
incubated at the temperature indicated in Table 1 below. 
Table 1: Incubation Temperatures 
 
 
 
 
 
Disk diffusion testing: A suspension of each fungal strain equivalent 
to McFarland standard 5 (approximately 1 x 109 CFU/mL)  was 
prepared in 5mL of sterile saline solution.  Using this standard 
suspension, Yeast Nutrient Base Agar was inoculated with a uniform 
lawn of a single fungi with a sterile swab and allowed to dry.  Disks 
were impregnated with 50 µg of test compound in 10 µL of 
methylene chloride.  Disks were also impregnated with 50 µg of 
clotrimazole in 10 µL of methylene chloride and 10 µl of methylene 
Species Temperature οC
C. albicans 37.0
C. glabrata 26.0
C. keyfr 37.0
C. krusei 26.0
C. lusitaniae 26.0
C. parapsilosis 37.0
C. tropicalis 37.0
C. utilis 26.0
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chloride, respectively as controls.  Disks were dispensed onto plates 
with a maximum of three disks per plate.  The plates were sealed 
with parafilm and incubated for 24-48 hours at the temperatures 
given in Table 1.  After 48 hours the cleared zones of inhibition were 
measured in mm and recorded. Each combination was tested 3 
times and an average zone was determined as the average of the 3 
measurements. 
 Specific trends in structure activity relationships are discussed in 
the next section. Overall, the disk study revealed varying degrees of 
antifungal activity for the N-thiolated β-lactams against 7 of the 8 
strains tested.  Most notable was the innate resistance of Candida 
krusei to all compounds tested.  
 
Structure-Activity Relationships 
Structure-activity relationships were analyzed using selections 
from the data obtained in the above study 
 20
. 
 
Effects of C4 Substitution on Antifungal Activities of N-Thiolated β- 
Lactams: 
 The effects of C4 substitution on antifungal activity are reflected 
in Table 2 through 10 and figures 11 through 19 and 21. Among 
halogenated aryl substituents, the fluoro (lactams 1-3) is the least 
effective; however antifungal activity does not uniformly increase 
with increasing molecular weight.  In fact, as found in antibacterial 
studies, it does not appear to be as important which halogen is on 
the phenyl ring, but rather how many halogens are there and where 
they are positioned.40 Fluoro- or chloro- substituents at the para 
postion on the benzene ring greatly reduce biological activity, which 
is not observed for the iodo-or bromo- substituents.  The presence 
of multiple fluoro- or chloro- substituents on the benzene ring seems 
to intensify activity. Also as seen in bacteria, unsaturation in the C4 
side chain generally seems to decrease activity,41 with the effect of 
the additional double bond being more pronounced than that of a 
triple bond. 
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Figure 11: Effects of Monofluorination on Antifungal Activities on N-
Thiolated β-Lactams 
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Table 2: Effects of Monofluorination on Antifungal Activities of N-
Thiolated β-Lactams 
Compound Concentration Organism Zone1 Zone2 Zone3 Average
Lactam 1 50 ug C. albicans 0 14 13 9
ortho F  C. tropicalis 1 1 1 1
  C. glabrata 0 0 0 0
  C. kefyr 16 14 15 15
  C. krusei 0 0 0 0
  C. lusitaniae 0 0 0 0
  C. parapsilosis 15 22 20 19
  C. utilis 14 14 15 14.33333
Lactam 2 50 ug C. albicans 15 12 14 13.66667
meta F  C. tropicalis 1 1 1 1
  C. glabrata 1 1 1 1
  C. kefyr 13 1 1 5
  C. krusei 0 0 0 0
  C. lusitaniae 1 1 1 1
  C. parapsilosis 25 19 22 22
  C. utilis 16 1 0 5.666667
Lactam 3 50 ug C .albicans 18 14 15 15.66667
para F  C. tropicalis 1 1 1 1
  C. glabrata 0 1 1 0.666667
  C. kefyr 1 1 1 1
  C. krusei 0 0 0 0
  C. lusitaniae 0 0 0 0
  C. parapsilosis 19 24 19 20.66667
  C. utilis 1 1 1 1
 
Zone sizes are measured in mm as the diameter around the disk 
where there is no visible growth. Partial inhibition (spotty zones) were 
defined as having a zone of 1mm.  No visible zone was defined as 
having a zone of 0mm. 
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Figure 12: Effects of Monochlorination on Antifungal Activities of N-
Thiolated β-Lactams 
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Table 3: Effects of Monochlorination on Antifungal Activities of N-
Thiolated β-Lactams 
Compound Concentration Organism Zone1 Zone2 Zone3 Average
Lactam 4 50 ug C. albicans 17 27 24 22.66667
Ortho Cl   C. tropicalis 19 23 20 20.66667
    C. glabrata 29 24 23 25.33333
    C. kefyr 20 15 16 17
    C. krusei 0 0 0 0
    C. lusitaniae 19 20 19 19.33333
    C. parapsilosis 36 29 33 32.66667
    C. utilis 21 23 21 21.66667
Lactam 5 50 ug C. albicans 23 24 21 22.66667
Meta Cl   C. tropicalis 21 19 21 20.33333
    C. glabrata 24 20 18 20.66667
    C. kefyr 15 11 13 13
    C. krusei 0 0 0 0
    C. lusitaniae 14 14 12 13.33333
    C. parapsilosis 21 29 33 27.66667
    C. utilis 13 23 21 19
Lactam 6 50 ug C. albicans 0 0 0 0
Para Cl   C. tropicalis 0 1 1 0.666667
    C. glabrata 0 0 0 0
    C. kefyr 11 9 10 10
    C. krusei 0 0 0 0
    C. lusitaniae 12 14 12 12.66667
    C. parapsilosis 0 1 1 0.666667
    C. utilis 0 0 0 0
 
Zone sizes are measured in mm as the diameter around the disk 
where there is no visible growth. Partial inhibition (spotty zones) were 
defined as having a zone of 1mm.  No visible zone was defined as 
having a zone of 0mm. 
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Figure 13: Effects of Monobromination on Antifungal Activities of N-
Thiolated β-Lactams 
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Table 4: Effects of Monobromination on Antifungal Activities of N-
Thiolated β-Lactams 
Compound Concentration Organism Zone1 Zone2 Zone3 Average
Lactam 7 50 ug C. albicans 25 27 25 25.66667
ortho Br   C. tropicalis 21 20 20 20.33333
    C. glabrata 16 16 17 16.33333
    C. kefyr 12 12 13 12.33333
    C. krusei 0 0 0 0
    C. lusitaniae 19 20 18 19
    C. parapsilosis 40 40 40 40
    C. utilis 25 25 25 25
Lactam 8 50 ug C. albicans 25 18 17 20
meta Br   C. tropicalis 24 16 15 18.33333
    C. glabrata 16 15 18 16.33333
    C. kefyr 13 13 14 13.33333
    C. krusei 0 0 0 0
    C. lusitaniae 14 15 14 14.33333
    C. parapsilosis 17 17 18 17.33333
    C. utilis 14 14 13 13.66667
Lactam 9 50 ug C. albicans 26 25 23 24.66667
para Br   C. tropicalis 21 18 20 19.66667
    C. glabrata 34 22 21 25.66667
    C. kefyr 20 16 15 17
    C. krusei 0 0 0 0
    C. lusitaniae 16 16 17 16.33333
    C. parapsilosis 23 24 22 23
    C. utilis 19 17 16 17.33333
 
Zone sizes are measured in mm as the diameter around the disk 
where there is no visible growth. Partial inhibition (spotty zones) were 
defined as having a zone of 1mm.  No visible zone was defined as 
having a zone of 0mm. 
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Figure 14: Effects of Monoiodination on Antifungal Activities of N-
Thiolated β-Lactams 
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Table 5: Effects of Monoiodination on Antifungal Activities of N-
Thiolated β-Lactams 
Compound Concentration Organism Zone1 Zone2 Zone3 Average
Lactam 10 50 ug C. albicans 20 14 14 16
ortho I   C. tropicalis 25 11 10 15.33333
    C. glabrata 19 18 22 19.66667
    C. kefyr 15 14 14 14.33333
    C. krusei 0 0 0 0
    C. lusitaniae 20 15 17 17.33333
    C. parapsilosis 20 22 25 22.33333
    C. utilis 15 15 14 14.66667
Lactam 11 50 ug C. albicans 26 13 15 18
meta I   C. tropicalis 18 12 13 14.33333
    C. glabrata 18 19 20 19
    C. kefyr 16 14 15 15
    C. krusei 0 0 0 0
    C. lusitaniae 20 17 20 19
    C. parapsilosis 19 22 24 21.66667
    C. utilis 14 17 15 15.33333
Lactam 12 50 ug C. albicans 16 15 17 16
para I   C. tropicalis 12 13 11 12
    C. glabrata 21 22 24 22.33333
    C. kefyr 20 17 19 18.66667
    C. krusei 0 0 0 0
    C. lusitaniae 22 17 21 20
    C. parapsilosis 23 24 29 25.33333
    C. utilis 19 21 20 20
 
Zone sizes are measured in mm as the diameter around the disk 
where there is no visible growth. Partial inhibition (spotty zones) were 
defined as having a zone of 1mm.  No visible zone was defined as 
having a zone of 0mm. 
 29
Figure 15: Effects of Multiple Fluorination on Antifungal Activities of N-
Thiolated β-Lactams 
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Table 6: Effects of Multiple Fluorination on Antifungal Activities of N-
Thiolated β-Lactams 
Compound Concentration Organism Zone1 zone2 Zone3 Average
Lactam 13 50 ug C. albicans 17 18 19 18
2,3,5 F   C. tropicalis 23 25 22 23.33333
    C. glabrata 1 11 1 4.333333
    C. kefyr 14 16 15 15
    C. krusei 0 0 0 0
    C. lusitaniae 15 18 17 16.66667
    C. parapsilosis 20 23 22 21.66667
    C. utilis 14 17 16 15.66667
Lactam 14 50 ug C. albicans 25 29 21 25
2,4,5 F   C. tropicalis 19 23 16 19.33333
    C. glabrata 14 14 13 13.66667
    C. kefyr 13 18 17 16
    C. krusei 0 0 0 0
    C. lusitaniae 15 14 14 14.33333
    C. parapsilosis 20 23 22 21.66667
    C. utilis 13 14 14 13.66667
Lactam 15 50 ug C. albicans 21 26 24 23.66667
3,4,5 F   C. tropicalis 19 20 18 19
    C. glabrata 17 18 17 17.33333
    C. kefyr 16 18 19 17.66667
    C. krusei 0 0 0 0
    C. lusitaniae 20 28 27 25
    C. parapsilosis 30 35 37 34
    C. utilis 20 33 34 29
 
Zone sizes are measured in mm as the diameter around the disk 
where there is no visible growth. Partial inhibition (spotty zones) were 
defined as having a zone of 1mm.  No visible zone was defined as 
having a zone of 0mm. 
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Figure 16: Effects of Multiple Chlorination on Antifungal Activities of N-
Thiolated β-Lactams 
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Table 7: Effects of Multiple Chlorination on Antifungal Activities of N-
Thiolated β-Lactams 
Compound Concentration Organism Zone1 Zone2 Zone3 Average
Lactam 16 50 ug C. albicans 22 23 22 22.33333
2,4 Cl   C. tropicalis 21 22 21 21.33333
    C. glabrata 33 29 30 30.66667
    C. kefyr 31 29 30 30
    C. krusei 1 0 1 0.666667
    C. lusitaniae 22 22 23 22.33333
    C. parapsilosis 24 27 28 26.33333
    C. utilis 19 18 19 18.66667
Lactam 17 50 ug C. albicans 22 23 22 22.33333
2,3,5 Cl   C. tropicalis 21 22 21 21.33333
    C. glabrata 33 29 30 30.66667
    C. kefyr 31 29 30 30
    C. krusei 1 0 1 0.666667
    C. lusitaniae 22 22 23 22.33333
    C. parapsilosis 24 27 28 26.33333
    C. utilis 19 18 19 18.66667
 
Zone sizes are measured in mm as the diameter around the disk 
where there is no visible growth. Partial inhibition (spotty zones) were 
defined as having a zone of 1mm.  No visible zone was defined as 
having a zone of 0mm. 
 
Effects of C3 Substitution on Antifungal Activities of N-Thiolated β-
Lactams: 
 The effects of methoxy, phenoxy and acetoxy groups at the C3 
position of the N-methylthio β-lactam were also investigated.  The 
results are displayed in Tables 9 and 10 and Figure 17. Both the 
bulky phenoxy and acetoxy groups reduced the activity of the 
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lactams with both  saturated and monounsaturated groups at the C4 
position.  The effect of the C3 acetoxy substituent on antifungal 
activity was less with a saturated group at the C4 position than with 
an unsaturated chain. 
 
 
Figure 17: Effects of C3 Substitution on Antifungal Activities of N-
Thiolated β-Lactams 
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Table 8: Effects of C3 Substitution on Antifungal Activities of N-
Thiolated β-Lactams 
Compound Concentration Organism Zone1 Zone2 Zone3 Average
Lactam 18 50 ug C. albicans 29 27 26 27.33333
MeO   C. tropicalis 15 14 14 14.33333
    C. glabrata 15 16 17 16
    C. kefyr 14 14 13 13.66667
    C. krusei 0 0 0 0
    C. lusitaniae 14 14 13 13.66667
    C. parapsilosis 13 13 12 12.66667
    C. utilis 18 20 20 19.33333
Lactam 19 50 ug C. albicans 0 0 0 0
AcO   C. tropicalis 0 0 0 0
    C. glabrata 12 14 15 13.66667
    C. kefyr 12 11 11 11.33333
    C. krusei 0 0 0 0
    C. lusitaniae 0 0 0 0
    C. parapsilosis 0 0 0 0
    C. utilis 13 14 13 13.33333
Lactam 20 50 ug C. albicans 0 0 0 0
PhO   C. tropicalis 0 0 0 0
    C. glabrata 9 10 9 9.333333
    C. kefyr 0 0 0 0
    C. krusei 0 0 0 0
    C. lusitaniae 0 0 0 0
    C. parapsilosis 0 0 0 0
    C. utilis 0 0 0 0
Lactam 21 50 ug C. albicans 34 34 34 34
MeO   C. tropicalis 20 15 15 16.66667
    C. glabrata 20 20 20 20
    C. kefyr 22 25 24 23.66667
    C. krusei 0 0 0 0
    C. lusitaniae 15 15 15 15
    C. parapsilosis 14 14 13 13.66667
    C. utilis 28 27 28 27.66667
Lactam 22 50 ug C. albicans 0 0 0 0
AcO   C. tropicalis 0 0 0 0
    C. glabrata 15 15 14 14.66667
    C. kefyr 13 13 14 13.33333
    C. krusei 0 0 0 0
    C. lusitaniae 0 0 0 0
    C. parapsilosis 0 0 0 0
    C. utilis 0 0 0 0
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Table 8 (continued)  
Lactam 23 50 ug C. albicans 24 25 24 24.33333
PhO   C. tropicalis 21 19 17 19
    C. glabrata 19 18 17 18
    C. kefyr 21 19 18 19.33333
    C. krusei 0 0 0 0
    C. lusitaniae 14 13 14 13.66667
    C. parapsilosis 14 13 14 13.66667
    C. utilis 22 20 20 20.66667
Zone sizes are measured in mm as the diameter around the disk 
where there is no visible growth. Partial inhibition (spotty zones) were 
defined as having a zone of 1mm.  No visible zone was defined as 
having a zone of 0mm. 
 
Effects of N-Substitution on Antifungal Activities of N-Thiolated β-
Lactams: 
 The effects of methylthio versus sec-butylthio substituents were 
next examined.  The sec-butylthio side chain resulted in a marked 
decrease in antifungal activity against 6 of the 8 Candida species 
examined as shown in Figure 18.  This represents a marked 
difference from the lactam’s antibacterial activity against 
Staphylococcus aureus, in which the sec-butylthio group increased 
activity of the lactams toward S. aureus and other bacteria screened 
relative to the methylthio.  
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Figure 18: Effects of N-Substitution on Antifungal Activities of N-
Thiolated β-Lactams 
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Table 9: Effects of N-Substitution on Antifungal Activities of N-
Thiolated β-Lactams 
Compound Concentration Organism Zone1 Zone2 Zone3 Average
Lactam 4 50 ug C. albicans 17 27 24 22.66667
Sme   C. tropicalis 19 23 20 20.66667
    C. glabrata 29 24 23 25.33333
    C. kefyr 20 15 16 17
    C. krusei 0 0 0 0
    C. lusitaniae 19 20 19 19.33333
    C. parapsilosis 36 29 33 32.66667
    C. utilis 21 23 21 21.66667
Lactam 24 50 ug C. albicans 16 15 16 15.66667
Sec Butyl   C. tropicalis 12 14 12 12.66667
    C. glabrata 0 0 0 0
    C. kefyr 0 0 0 0
    C. krusei 0 0 0 0
    C. lusitaniae 0 0 0 0
    C. parapsilosis 0 0 0 0
    C. utilis 0 0 0 0
 
Zone sizes are measured in mm as the diameter around the disk 
where there is no visible growth. Partial inhibition (spotty zones) were 
defined as having a zone of 1mm.  No visible zone was defined as 
having a zone of 0mm. 
 
Effect of Absolute Stereochemistry on Antifungal Activities of N-
Thiolated β-Lactams: 
 Chiral antibiotics are typically more active in one enantiomeric 
form than the other.  The less active enantiomer can also produce 
unwanted side effects. Thus, the issue of absolute stereochemistry 
of the lactams on antifungal activity was assessed using 
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enzymatically purified enantiomers of the lactam. Lipase PS-30 was 
used to selectively deacylate the 3S,4R 3-acetoxy derivative of the 
lactam. The resulting (-) alcohol and (+) acetate compounds could 
then be separated and independently converted into the 
corresponding N-methylthio β-lactam as shown in Figure 19.42 
N
O
OCH3
AcO
Lipase PS-30
acetone
phosphate buffer
pH 7.2
N
O
OCH3
HO
N
O
OCH3
AcO
+
N
O SMe
AcO
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Lactam 25 (-) Lactam 25(+)  
Figure 19: Enzymatic Purification of Lactam 25 
 
The (+) and (–) enantiomers were compared in a disk diffusion 
assay.  The (-) enantiomer had significantly less in activity againt C. 
lusitiniae and C. utilis and a more modest decrease in activity 
against C. parapsilosis and C. tropicalis as shown in Figure 20.  
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There was little difference in activity between the two enantiomers 
against C. albicans.  
This is different from what was found against S. aureus where 
absolute stereochemistry was not found to have any effect 
whatsoever.  This suggests that unlike in bacteria, there may be 
some nonbonding interactions of the lactam with the biological 
target in some species of Candida.   
 
Figure 20: Effects of (+) and (-) Enantiomers of Lactam 25 on 
Antifungal Activities of N-Thiolated β-Lactams 
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Table 10: Effects of (+) and (-) Enantiomers of Lactam 25 on 
Antifungal Activities of N-Thiolated β-Lactams 
Compound Concentration Organism Zone1 Zone2 zone3 Average
Lactam 25 50 ug C. albicans 14 15 14 14.33333
(+) enantiomer   C. tropicalis 14 15 15 14.66667
    C. glabrata 0 0 0 0
    C. kefyr 9 10 9 9.333333
    C. krusei 0 0 0 0
    C. lusitaniae 15 15 14 14.66667
    C. parapsilosis 0 0 0 0
    C. utilis 16 15 16 15.66667
Lactam 26 50 ug C. albicans 14 13 13 13.33333
(-) enantiomer   C. tropicalis 10 11 13 11.33333
    C. glabrata 0 0 0 0
    C. kefyr 0 0 0 0
    C. krusei 0 0 0 0
    C. lusitaniae 10 11 10 10.33333
    C. parapsilosis 0 0 0 0
    C. utilis 16 15 16 15.66667
Zone sizes are measured in mm as the diameter around the disk 
where there is no visible growth. Partial inhibition (spotty zones) were 
defined as having a zone of 1mm.  No visible zone was defined as 
having a zone of 0mm. 
 
 
The data in this study reveal some interesting trends in the 
structure-activity profile of these lactams.  In general they support 
what has already been found in the structure-activity studies of 
these lactams against bacteria. As in bacteria, differences in the 
biological activity of different lactams may be more closely related 
to their ability to diffuse across the cellular membrane than to any 
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specific binding interaction with a biological target despite there 
being some evidence of nonbonding interactions. 
 
Minimum Inhibitory Concentration 
As lactam 4 was soluble in a 1% aqueous solution of DMSO, 
minimum inhibitory concentrations for that compound were 
determined using two different methods. 
MICs by Agar Diffusion 
Lactam 4 was tested against C. albicans, C. tropicalis, C. 
glabrata, C. lusitinae, C. parapsilosis, C. utilis, and C. keyfr. Yeast 
Nitrogen Agar was prepared and a 1mg/mL solution of lactam 4 in 
DMSO was prepared.  Each well of a 48 well (1.5 mL) plastic plate 
was filled with different amounts of lactam 4, from 0-50 ug in 5 ug 
increments.  Agar was added to bring the total volume of each well 
to 1 mL, stirred, and allowed to harden overnight.  Each well was 
then inoculated with 1uL of a standardized solution of 106 CFU/mL of 
fungi suspended in sterile NaCl.  A separate plate prepared with 
wells containing 0-50 ug of lactam 4 was used for each species to 
prevent cross contamination.  The results are shown in Table 11.
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Table 11: Minimum Inhibitory Concentration Values Determined 
for Lactam 4 by Agar Dilution 
 
Candida sp. MIC 24 hrs. MIC 48 hrs. 
C. albicans <5 ug/ml <5 ug/ml 
C. tropicalis 10-15 ug/ml 30-35 ug/ml 
C. glabrata 10-15 ug/ml 10-15 ug/ml 
C. kefyr 10-15 ug/ml 35-40 ug/ml 
C. lusitaniae 10-15 ug/ml 15-20 ug/ml 
C. parapsilosis <5 ug/ml <5 ug/ml 
C. utilis 10-15 ug/ml 15-20 ug/ml 
 
The MIC was significantly higher at 48 hours than at 24 hours.  
This may be an effect of the fungi overcoming the concentration of 
compound on the surface of the well. This suggests that the 
compound may be fungistatic versus fungicidal. 
These MICs at both 24 and 48 hours are significantly higher than 
the literature value of MICs for fluconazole, amphotericin B, and 
nystatin. 
 
MICs Broth Macrodilution 
The minimum inhibitory concentration was also determined in 
triplicate using the NCCLS broth macrodilution method for water 
insoluble antifungal agents described in document M27-A243 with 
incubation for24 hours.  This standardized testing method allows for 
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better quality control and comparison to known standards 
(clotrimazole and amphotericin B). 
 
Table 12: Minimum Inhibitory Concentration Values for Lactam 4 
Determined by Broth Macrodilution 
Agent MIC (ug/mL)
Clotrimazole 2
Amphotericin B <0.313
Lactam 4 8  
 The MIC for Amphotericin B was within the cited range of .25 – 
1.0 ug/mL against C. albicans. 
 
 The MIC values as determined by this method are slightly lower 
than that found with the agar dilution method. Although broth and 
agar dilution have been found to be comparable, this could be an 
artifact of the two different testing methods as they were performed 
in different types of media (Yeast Nutient versus RPMI).  However 
this value is still significantly higher than either drug currently in 
use. The comparatively high concentrations of lactam 4 necessary 
for activity in broth would be presumably more difficult to achieve in 
vivo.
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Chapter Three 
Studies Leading Towards Mode of Action 
Three studies were undertaken toward finding the mode of action of 
these lactams;  
1. An assay was performed to determine whether the drug has a 
fungistatic or fungicidal effect on fungi 
2. A broth study was performed to investigate the products of the 
molecule’s interaction with fungal cells 
3. A TEM study was performed to visualize any ultrastructural 
effects the drug might have on the cells. 
Fungistatic versus Fungicidal 
A tube with 20 mL of Yeast Nutrient Broth was inoculated with a 
colony of C. albicans that had been cultured for 48 hours on agar.  
This then was incubated at 37 oC for 18 hours.  
Two sets of tubes were prepared from this culture.  Each tube 
contained 4.8 mL culture and 200 uL of either DMSO or lactam 4 
dissolved in DMSO (1ug/uL). Two sets of a series of dilutions (full  
strength, 1:10, 1:1000) were prepared, and initial plate counts 
performed.  These tubes were incubated at 37 oC overnight. 
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After incubation another set of plate counts were performed to 
determine the effect that the drug had on the growth of the fungi. 
The fungal growth was slowed by the addition of Lactam 4 as shown 
by the dip in the red lines in Figure 10.  
The cells were then washed in PBS and resuspended in nutrient 
broth and incubated overnight to see if growth would resume after 
removal of the compound.  
 
Figure 21: Growth Study: Effect of Lactam 4 on Growth of Candida 
albicans 
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The fact that growth was slowed by the drug, but resumed upon its 
removal, indicates that the drug has a fungistatic effect. This 
supports previous studies in bacteria showing an inhibitory rather 
than a cidal effect. The ability of the fungi to overcome the 
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antifungal effects of the drug is another indicator that it would take 
relatively high in vivo concentrations of the drug for it to be effective 
in treatment. 
 
Broth Study 
Vials were prepared with 9 mL of yeast nutrient base broth and 1 
mL of 1 mg/mL solution of lactam 4 in DMSO.  Vials were inoculated 
with one loopful of C. albicans and vortexed.  One vial was incubated 
for 2 hours at room temperature and another was incubated for 72 
hours at room temperature.  Controls were set up with  
1) Yeast nutrient base broth, 1 mL of DMSO, and a loopful of C. 
albicans  
2) Yeast nutrient base broth, 1 mg/mL solution of  lactam 4 in 
DMSO, but no C. albicans  
Controls were incubated at room temperature for 72 hours. 
After the given incubation period each solution was extracted 
with 5 mL of ethyl acetate.  The organic layer was removed and this 
was repeated twice more.  The three organic layers were combined, 
dried with magnesium sulfate and evaporated to remove solvent.  
The remaining residues were examined with NMR to ascertain 
identity of products.  
This procedure was repeated with saline replacing yeast nutrient 
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base broth with incubation times of 2 hours, 24 hours and 72 hours 
with controls being incubated for 72 hours. 
The broth study of lactam 4 revealed that a complete removal of 
the methylthio group from the nitrogen occurred after 24 h in both 
saline as well as broth both with and without C. albicans.  The ring 
structure was left intact.  No change from the original lactam 
structure was observed in any of the controls.  At 2 hours a mixture 
of the original lactam structure and that of the lactam with the 
methylthio group removed was observed.  Spectra are located in 
Appendix B. 
The results of the broth study revealed a complete conversion to 
the N-H analogue after 24 hours in the presence of the microbe with 
the ring structure left intact.  This is quite different from that of 
older β-lactams, but similar to what has been seen with these 
lactams towards bacteria and strongly suggests a distinct mode of 
action possibly involving the transfer of the methylthio group to a 
protein. 
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Transmission Electron Microscopy (TEM) Study 
Since fluorescent labeling of one of the N-methylthio lactams in 
an effort to elucidate the mode of action proved difficult, a TEM 
study to investigate ultrastructural changes in fungl cells caused by 
the lactam was performed. 
Method: A culture of C. albicans was grown from the frozen glycerol 
stock on yeast nutrient agar incubated at 37 oC for 48 hours. From 
this culture, liquid Saraboud’s dextrose medium was inoculated and 
incubated at 37 oC on a reciprocal shaker until exponential growth 
was achieved.  At the exponential phase portions of the culture were 
added to 2 tubes each containing the MIC of either Lactam 4 or 
Clotrimazole dissolved in 1% aqueous DMSO. One tube of each 
antifungal compound was incubated for 1h and the other for 4 h with 
aeration.  Tubes were also prepared as the control with only 1% 
aqueous DMSO added instead and incubated for 1h and 4h with 
aeration.  After incubation the cells were pelleted and washed twice 
with 0.1M phosphate buffer (pH 7.2). 
 The washed pellet from each culture was resuspended in 2.5% 
aqueous glutaraldehyde in 0.1M phosphate buffer at 4oC for 2h.  The 
cells were pelleted and post fixed in 1.5% aqueous potassium 
permanganate at 4oC overnight.  The cells were then washed in 
deionized water and agar embedded.  The agar embedded cells were 
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en-block stained with 1.5% aqueous uranyl acetate for 1.5 h at 
room temperature. They were then dehydrated in a series of 
acetone washes, infiltrated, and embedded in Spurr’s Plastic.  Blocks 
were trimmed and sectioned with a Sorvall MT-2B ultamicrotome 
and put on copper mesh grids.  Grids were stained with 2% uranyl 
acetate and viewed with an FEI Morgani 268D Electron Microscope. 
The images in Appendix C revealed little ultrastructural damage 
to organelles in the cells.  There was no membrane degradation, no 
leakage of cell contents and no damage to the cell wall or 
mitochondria.  This suggests a mode of action distinct from that of 
most other antifungals which target ergosterol and result in visible 
damage to the cell membranes. 
Given the observed structure-activity relationship, fungistatic 
effect, lack of ultratructural damage induced, and spectra of the 
products of the drug’s interection with the cell, it is postulated that 
the mode of action of these antifungals is similar to that seen in 
bacteria37,44 consisting of a thiol transfer to a biological target 
(Figure 22).   
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Figure 22: Proposed mechanism of action 
We postulate that these lactams, after passing through the cell 
membrane, interact covalently with a biological target resulting in a 
transfer of the sulfur side chain.  This mechamism is primarily 
supported by the spectra of the product isolated with the lactam 
intact and the sulfur side chain missing. This is further supported by 
the structure-activity relationship in that the sulfur side chain is 
strictly required for activity, that groups at C3 and C4 which are 
highly polar exhibit little to no activity and that groups which are 
highly lipophilic may cause trapping in the membrane or organelles 
and exhibit reduced activity.  This interaction in fungi is more 
specific than in bacteria in that both absolute stereochemistry and 
bulky side chains at the thio group affect activity.  Thus, the cellular 
target (Nu H) attacked is likely evolutionarily conserved such as a 
common metabolic enzyme or intermediate with a slightly different 
structure in bacteria and fungi.  Further study is needed to elucidate 
the identity of this target and its interaction with the N-thiolated 
lactam. 
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Chapter Four 
Discussion 
As described in the introduction, Candida infections have become a 
significant problem in terms of medical cost, morbidity and mortality. 
These infections are and will continue to be a growing problem as even 
the newest of drugs have documented resistance.  Thus the continuing 
search for and development of novel antifungals is important. 
This study has investigated the antifungal activity of a new series of 
nonconventional β-lactams. Several analogs of these lactams were 
shown to have activity against the most common Candida pathogens. 
Unlike in other reported bactrio-and fungistatic lactams these seem to 
work through a similar mode of action in both S. aureus and C. 
albicans. These lactams were found to have similar structure activity 
relationships in both S. aureus and C. albicans. As previously reported 
in antibacterial structure activity studies against these monocyclic 
lactams, it does not appear to be as important which halogen is on the 
phenyl ring, but rather how many halogens are there and where they 
are positioned, that the sulfur side chain is strictly required for activity, 
that groups at C 3 and C 4 which are highly polar exhibit little to no 
activity, and that groups which are highly lipophilic exhibit reduced 
activity.   The interaction between drug and target in fungi however 
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seems to be more specific than in bacteria in that both absolute 
stereochemistry and bulky side chains at the thio group decrease 
activity in fungi, but not in bacteria.   As with S. aureus, the broth 
study revealed complete removal of the methylthio group from the 
nitrogen upon interaction of the drug with Candida.   The ring 
structure was left intact. Upon visualization of treated Candida cells, 
there was no membrane degradation, no leakage of cell contents and 
no damage to the cell wall or mitochondria.  The spectrum of activity, 
structure-activity relationships, and preliminary studies toward 
determining the mode of action support a unique mode of action in 
Candida fungi similar to that observed in S. aureus. We postulate that 
these lactams, after passing through the cell membrane, interact 
covalently with a biological target resulting in a transfer of the sulfur 
side chain to some common target.  
          Though the high MIC of these compounds make them a poor 
candidate for clinical use as antifungals, understanding the mode of 
action of these as well as other novel lactams and how their mode of 
action affects other pathways in the cell could lead to development of 
new drugs or new ways to combat fungal resistance to current drugs.  
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Appendix A: NMR Spectra of Lactams Synthesized 
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Lactam 4 
 
 
 
Lactam 4 NH Intermediate 
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Lactam A  
 
 
Lactam B 
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Lactam A and B NH Intermediate 
 
 
Lactam A and B PMP Intermediate 
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Appendix B: NMR Spectra from Broth Study 
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Control Extract Broth Only: shows background from components of 
broth 
 
Control Extract Lactam 4 + Broth: shows intact lactam in broth after 
24 hours 
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Extract of Lactam 4 + C. albicans + Broth 24 hours: shows conversion 
to NH lactam 
 
Extract of Lactam 4 + C. albicans + Saline 24 hours: shows conversion 
to NH lactam 
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Appendix C: TEM Images 
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Comparison of Whole Cell 
 
Candida + Lactam 4 (4 Hour 
Incubation) showing no visible damage to cell wall, cell membranes or organelles as 
compared to control 
 
Candida Control 
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Comparison of Close up of Nuclei 
 
 Candida + Lactam 4 (4 Hour 
Incubation) showing no visible damage to nucleus as compared to control 
 
 Candida Control 
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Comparison of Close up of Mitochondria 
 
 Candida + Lactam 4 (4 Hour 
Incubation) showing no visible damage to mitochondria compared to control 
 
 Candida Control 
